(Reuters) - Rare disease drugmaker PTC Therapeutics Inc (O:PTCT) is exploring a potential sale amid takeover interest from several pharmaceutical companies including Shire PLC (L:SHP) and BioMarin Pharmaceutical Inc (O:BMRN), according to people familiar with the matter.
The South Plainfield, New Jersey-based company, which treats a muscle wasting disorder known as Duchenne, is working with financial advisers as it weighs strategic alternatives, the people said, asking not to be named because the matter is private.
Representatives for PTC Therapeutics, which has a market valuation of roughly $2 billion (1.3 billion pounds), could not be reached for comment. Representatives for Shire and BioMarin declined to comment.